StockStory Flags Stryker for Growth, Cites AT&T and Berkshire Hathaway Concerns

StockStory has identified Stryker as an S&P 500 candidate with solid fundamentals while flagging AT&T and Berkshire Hathaway for potential underperformance. The analysis, which examines specific financial metrics for each company, suggests that not all constituents of the benchmark index offer equal investment value.

AT&T, a multinational telecommunications conglomerate founded by Alexander Graham Bell, is the first stock the platform views with a bearish outlook. The company has a market capitalization of $170.4 billion. StockStory notes that AT&T sales remained flat over the last five years, indicating a failure to expand its business. During the same period, earnings per share fell by 6.9% annually while revenue stayed static, implying that each sale became less profitable. The platform also points to forecasted free cash flow margins, suggesting the company will not improve its cash conversion over the next year. AT&T shares trade at $23.24, corresponding to a forward price-to-earnings ratio of 10.2 times.

Berkshire Hathaway, led by Warren Buffett since 1965, is described as a diversified holding company with interests in insurance, railroads, utilities, manufacturing, retail, and services. With a market capitalization of $1.09 trillion, the company faces cautious sentiment from StockStory due to its massive scale, which the platform argues limits growth potential compared to smaller rivals. Annual revenue increases averaged just 4.2% over the last five years, a figure the analysis describes as below average. Additionally, earnings per share lagged peers over the last two years, growing at an annual rate of only 7%. Berkshire Hathaway shares are priced at $766,566, trading at a forward price-to-earnings ratio of 22.6 times.

In contrast, Stryker is positioned as a potential winner. The medical device manufacturer impacts over 150 million patients annually through technologies in orthopedics, surgical tools, neurotechnology, and patient care solutions. Its market capitalization stands at $106.2 billion. StockStory highlights that Stryker's core business generates organic revenue growth averaging 9.2% over the past two years without relying on acquisitions. The company also benefits from economies of scale that provide greater fixed cost leverage than smaller competitors. Notably, free cash flow margin increased by 6.5 percentage points over the last five years, providing resources for growth initiatives, share repurchases, or dividends. Stryker trades at $276.25 per share, implying a valuation ratio of 17.3 times forward earnings.

The analysis is part of a broader effort by StockStory to navigate market complexities. The platform recently flagged growth stocks such as Meta, CrowdStrike, and Broadcom based on revenue expansion metrics. It also noted past performers like Nvidia and Exlservice from its 2020 list.